Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 18 | 2023 | 2231 | 3.330 |
Why?
|
| Heart Transplantation | 7 | 2021 | 747 | 2.220 |
Why?
|
| Heart-Assist Devices | 6 | 2022 | 552 | 2.180 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 319 | 1.050 |
Why?
|
| Cardiology | 2 | 2020 | 274 | 1.000 |
Why?
|
| Patient Selection | 2 | 2020 | 691 | 0.980 |
Why?
|
| Stroke Volume | 5 | 2023 | 612 | 0.920 |
Why?
|
| Hospice Care | 2 | 2023 | 202 | 0.820 |
Why?
|
| Registries | 5 | 2019 | 2015 | 0.820 |
Why?
|
| Medicare | 3 | 2023 | 758 | 0.760 |
Why?
|
| Defibrillators, Implantable | 2 | 2016 | 315 | 0.750 |
Why?
|
| Cardiovascular Agents | 1 | 2022 | 160 | 0.700 |
Why?
|
| Home Care Services | 1 | 2023 | 257 | 0.670 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2022 | 382 | 0.660 |
Why?
|
| Waiting Lists | 2 | 2019 | 262 | 0.660 |
Why?
|
| BK Virus | 1 | 2019 | 14 | 0.650 |
Why?
|
| Population Health | 1 | 2020 | 47 | 0.640 |
Why?
|
| Immunocompromised Host | 2 | 2020 | 202 | 0.610 |
Why?
|
| Patient Advocacy | 1 | 2019 | 75 | 0.610 |
Why?
|
| Viremia | 1 | 2019 | 138 | 0.600 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2016 | 46 | 0.590 |
Why?
|
| Triage | 1 | 2020 | 221 | 0.560 |
Why?
|
| Renal Insufficiency | 1 | 2019 | 155 | 0.560 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2018 | 87 | 0.540 |
Why?
|
| Organizational Objectives | 1 | 2017 | 73 | 0.540 |
Why?
|
| Betacoronavirus | 1 | 2020 | 266 | 0.540 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 104 | 0.530 |
Why?
|
| Health Policy | 1 | 2020 | 385 | 0.530 |
Why?
|
| Heart Diseases | 1 | 2020 | 346 | 0.520 |
Why?
|
| Pacemaker, Artificial | 1 | 2018 | 119 | 0.510 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2016 | 11 | 0.510 |
Why?
|
| Cardiovascular System | 1 | 2017 | 137 | 0.490 |
Why?
|
| Electric Countershock | 1 | 2016 | 107 | 0.480 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 935 | 0.480 |
Why?
|
| Mentors | 1 | 2017 | 200 | 0.470 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 368 | 0.470 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 358 | 0.460 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 443 | 0.460 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2016 | 185 | 0.460 |
Why?
|
| Mentoring | 1 | 2017 | 144 | 0.450 |
Why?
|
| Health Services Research | 1 | 2017 | 400 | 0.450 |
Why?
|
| Primary Prevention | 1 | 2016 | 196 | 0.450 |
Why?
|
| Quality Improvement | 2 | 2020 | 1163 | 0.390 |
Why?
|
| Medication Adherence | 1 | 2016 | 468 | 0.380 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 389 | 0.370 |
Why?
|
| Biomedical Research | 1 | 2017 | 688 | 0.350 |
Why?
|
| Humans | 28 | 2023 | 136803 | 0.340 |
Why?
|
| United States | 9 | 2023 | 14691 | 0.330 |
Why?
|
| Insurance, Health | 3 | 2021 | 280 | 0.330 |
Why?
|
| Aged, 80 and over | 5 | 2023 | 7593 | 0.280 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2019 | 103 | 0.270 |
Why?
|
| Female | 15 | 2023 | 72816 | 0.240 |
Why?
|
| Patient Readmission | 2 | 2022 | 694 | 0.220 |
Why?
|
| Treatment Outcome | 6 | 2020 | 10748 | 0.210 |
Why?
|
| Aged | 9 | 2023 | 23808 | 0.200 |
Why?
|
| Male | 13 | 2023 | 67330 | 0.200 |
Why?
|
| Risk Factors | 3 | 2023 | 10332 | 0.190 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 1301 | 0.180 |
Why?
|
| Community-Based Participatory Research | 1 | 2022 | 160 | 0.180 |
Why?
|
| Insurance Carriers | 1 | 2021 | 11 | 0.170 |
Why?
|
| Logistic Models | 2 | 2016 | 2067 | 0.170 |
Why?
|
| Pericarditis | 1 | 2020 | 10 | 0.170 |
Why?
|
| Aftercare | 1 | 2022 | 207 | 0.170 |
Why?
|
| Cryptococcus neoformans | 1 | 2020 | 21 | 0.170 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 2822 | 0.170 |
Why?
|
| Cryptococcosis | 1 | 2020 | 27 | 0.170 |
Why?
|
| Cardiologists | 1 | 2020 | 45 | 0.160 |
Why?
|
| Patient Participation | 2 | 2021 | 418 | 0.160 |
Why?
|
| Retrospective Studies | 5 | 2023 | 15510 | 0.160 |
Why?
|
| Hospitalization | 2 | 2023 | 2184 | 0.160 |
Why?
|
| Hospices | 1 | 2021 | 87 | 0.160 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 5106 | 0.150 |
Why?
|
| Coronary Artery Bypass | 1 | 2021 | 233 | 0.150 |
Why?
|
| Guidelines as Topic | 1 | 2021 | 276 | 0.150 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 402 | 0.150 |
Why?
|
| Risk Assessment | 2 | 2020 | 3434 | 0.150 |
Why?
|
| Cardiotonic Agents | 1 | 2019 | 124 | 0.150 |
Why?
|
| Adult | 8 | 2021 | 37643 | 0.150 |
Why?
|
| Viral Load | 1 | 2019 | 464 | 0.140 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 62 | 0.140 |
Why?
|
| Community Health Services | 1 | 2019 | 227 | 0.140 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2017 | 43 | 0.130 |
Why?
|
| Long-Term Care | 1 | 2018 | 106 | 0.130 |
Why?
|
| Time Factors | 3 | 2016 | 6809 | 0.130 |
Why?
|
| Professional Competence | 1 | 2017 | 100 | 0.130 |
Why?
|
| Patient Safety | 1 | 2020 | 308 | 0.130 |
Why?
|
| Stakeholder Participation | 1 | 2017 | 77 | 0.130 |
Why?
|
| Cohort Studies | 2 | 2018 | 5704 | 0.130 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 191 | 0.130 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2016 | 16 | 0.120 |
Why?
|
| Patient Discharge | 1 | 2022 | 894 | 0.120 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2016 | 54 | 0.120 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 649 | 0.120 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2021 | 478 | 0.120 |
Why?
|
| Career Choice | 1 | 2017 | 216 | 0.120 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1481 | 0.120 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 150 | 0.120 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 530 | 0.120 |
Why?
|
| Interprofessional Relations | 1 | 2017 | 281 | 0.110 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 201 | 0.110 |
Why?
|
| Propensity Score | 1 | 2016 | 289 | 0.110 |
Why?
|
| Caregivers | 1 | 2022 | 870 | 0.110 |
Why?
|
| Physicians | 1 | 2023 | 907 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 587 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 698 | 0.110 |
Why?
|
| Postoperative Care | 1 | 2016 | 261 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2017 | 385 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 888 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2019 | 739 | 0.110 |
Why?
|
| Dyspnea | 1 | 2015 | 254 | 0.100 |
Why?
|
| Survival Rate | 1 | 2018 | 1964 | 0.100 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 1262 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1231 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2016 | 1321 | 0.100 |
Why?
|
| Medicaid | 1 | 2017 | 433 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 1163 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 522 | 0.090 |
Why?
|
| Pandemics | 1 | 2020 | 1616 | 0.090 |
Why?
|
| Curriculum | 1 | 2017 | 976 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1507 | 0.090 |
Why?
|
| Age Factors | 1 | 2018 | 3286 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2019 | 2639 | 0.070 |
Why?
|
| Middle Aged | 6 | 2021 | 33239 | 0.070 |
Why?
|
| Exercise Test | 2 | 2021 | 625 | 0.060 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 5744 | 0.060 |
Why?
|
| Pericardiocentesis | 1 | 2020 | 9 | 0.040 |
Why?
|
| Fluconazole | 1 | 2020 | 19 | 0.040 |
Why?
|
| Fee-for-Service Plans | 1 | 2021 | 85 | 0.040 |
Why?
|
| Health Services Misuse | 1 | 2020 | 33 | 0.040 |
Why?
|
| Focus Groups | 1 | 2023 | 515 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2020 | 136 | 0.040 |
Why?
|
| Income | 1 | 2020 | 203 | 0.040 |
Why?
|
| Echocardiography | 1 | 2020 | 643 | 0.030 |
Why?
|
| Organ Transplantation | 1 | 2020 | 248 | 0.030 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 257 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 418 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2017 | 130 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 548 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2015 | 99 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2017 | 229 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1786 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 846 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 1462 | 0.030 |
Why?
|
| Palliative Care | 1 | 2021 | 752 | 0.030 |
Why?
|
| Decision Making | 1 | 2021 | 898 | 0.030 |
Why?
|
| Acute Disease | 1 | 2015 | 1007 | 0.020 |
Why?
|
| Young Adult | 2 | 2021 | 13129 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 951 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2015 | 705 | 0.020 |
Why?
|
| Adolescent | 2 | 2021 | 21385 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 4013 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 4145 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2015 | 7573 | 0.010 |
Why?
|